Does Anthem Cover Adderall?

Anthem's Formulary Placement for Adderall

Generic mixed amphetamine salts in the immediate-release (IR) formulation sit on Tier 2 of most Anthem commercial and Marketplace formularies, which means preferred-generic status. Brand-name Adderall IR has been discontinued by Teva, so the generic is the default dispensed product. Adderall XR (extended-release) generics from Teva, Sandoz, and Impax are placed on Tier 2 or Tier 3 depending on the specific plan document.

Anthem's publicly available 2024 and 2025 formulary PDFs confirm that mixed amphetamine salts IR 5 mg through 30 mg tablets carry a "G" (generic) designation with no prior authorization flag for most employer-sponsored plans [1]. The XR capsule generics, however, carry a "PA" (prior authorization) and "ST" (step therapy) flag on many exchange and Medicaid managed-care formularies.

The distinction matters. An IQVIA analysis of U.S. prescription claims data found that 78% of all amphetamine salt combination prescriptions filled in 2024 were generic IR tablets, and the average out-of-pocket cost for insured patients was $28.40 per fill [2]. The same report showed average out-of-pocket costs for branded extended-release stimulants exceeding $147 per fill even with insurance.

Anthem contracts pharmacy benefit management through either IngenioRx (its in-house PBM) or, for certain legacy plans, Express Scripts. The formulary tier, copay, and PA requirements vary by which PBM manages the plan. Checking your specific formulary at anthem.com/pharmacyinformation or calling the member services number on your card is the most reliable method for confirming coverage.

Prior Authorization Requirements

Anthem requires prior authorization for Adderall in several specific scenarios. The three most common triggers are requests for brand-name product when a generic equivalent exists, doses exceeding 40 mg per day in adults (or 30 mg/day in children under 12), and initial prescriptions from non-psychiatric providers in some Medicaid managed-care plans.

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline for ADHD states: "For elementary school-aged children (6 through 11 years of age), the clinician should prescribe FDA-approved medications for ADHD and/or evidence-based parent- and/or teacher-administered behavior therapy as treatment for ADHD, preferably both" [3]. Anthem's prior authorization criteria generally align with this recommendation, requiring a documented ADHD diagnosis using DSM-5 criteria before approving coverage.

For adults, Anthem's clinical policy bulletin references the FDA-approved prescribing information for mixed amphetamine salts, which indicates a maximum recommended dose of 40 mg/day for ADHD in adults [4]. Requests above this threshold require documentation of inadequate response at lower doses plus a prescriber attestation that benefits outweigh cardiovascular risks.

The PA turnaround time is 72 hours for standard requests and 24 hours for urgent requests where the patient has already been stabilized on the medication. Your prescriber submits the request via Availity, fax, or the Anthem provider portal. Denials come with a specific clinical rationale and instructions for peer-to-peer review.

Step Therapy: What Anthem Requires You to Try First

Step therapy is Anthem's biggest practical barrier to Adderall XR coverage. Most commercial and exchange plans require a documented 30-day trial of generic mixed amphetamine salts IR before approving coverage for any extended-release amphetamine product.

This policy reflects cost management strategy, not clinical inferiority of IR formulations. A meta-analysis published in the Journal of the American Academy of Child and Adolescent Psychiatry (Faraone et al., 2006) found that both IR and XR stimulant formulations produced clinically meaningful ADHD symptom reduction, with effect sizes of 0.91 and 0.95 respectively [5]. The clinical difference is primarily in duration of action (4 to 6 hours for IR versus 8 to 12 hours for XR) and adherence convenience.

To satisfy step therapy, you need documentation showing one of these outcomes from the IR trial: inadequate symptom control despite dose optimization, intolerable adverse effects (e.g., significant rebound symptoms or appetite suppression requiring split dosing), or a clinical scenario where twice- or three-times-daily dosing creates adherence risk (common in school-aged children and college students). Your prescriber must include this documentation in the step therapy exception request.

Some plans also accept a trial of methylphenidate (generic Ritalin or Concerta) as a first step before approving any amphetamine product. Check whether your plan's step therapy requires a trial of a different molecule class or only a different formulation of the same molecule.

How Much Will You Pay Out of Pocket?

Out-of-pocket cost depends on your plan's tier structure, whether you have met your deductible, and which pharmacy you use. Here is a realistic cost breakdown for Anthem members filling generic mixed amphetamine salts.

For commercial employer plans with standard copay structure: Tier 2 generic copays run $10 to $30 for a 30-day supply at a preferred pharmacy. Mail-order (typically 90-day supply) reduces the per-month cost by 20% to 40% on most Anthem plans.

For Anthem Marketplace (ACA exchange) plans: Bronze-tier plans often apply the full cost to the deductible until it is met, meaning you pay the cash price ($30 to $65 for generic IR) until your deductible is satisfied. Silver and Gold plans more frequently have flat copays ranging from $15 to $45 even before the deductible.

A 2023 analysis of ADHD medication costs in the American Journal of Managed Care found that the mean annual out-of-pocket spending for insured patients on generic stimulants was $342 ($28.50/month), compared with $1,764 ($147/month) for branded formulations [6]. Switching from brand Adderall XR to generic reduced annual patient spending by an average of $1 to 422 in the study cohort.

For Medicaid managed-care plans administered by Anthem: generic stimulants are covered at $0 to $3 copay in most states. Brand products require both PA and a documented medical necessity for the specific brand. Anthem's Medicaid formularies in Ohio, Indiana, Georgia, and Virginia all list generic mixed amphetamine salts as preferred [7].

GoodRx and similar discount programs price generic mixed amphetamine salts IR (30 tablets of 20 mg) between $25 and $55 at major chains, which can occasionally beat a high-deductible plan's cost. Compare your insurance copay to the cash discount price before filling.

Adderall XR vs. IR: Coverage Differences on Anthem Plans

The coverage gap between IR and XR formulations is one of the most common sources of confusion for Anthem members. Generic IR tablets are almost universally covered at Tier 2 with no PA. Generic XR capsules are covered on most plans but frequently carry PA and step therapy requirements, placing them functionally at Tier 3 until prior authorization is approved.

Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "Extended-release formulations offer meaningful clinical advantages for patients who need all-day coverage, particularly children in school settings where midday dosing is impractical or stigmatizing" [8]. This clinical rationale is exactly the kind of documentation that supports a successful step therapy exception.

If your prescriber determines that XR is medically necessary from the start (for example, a child who cannot take medication at school due to nurse unavailability, or an adult with a job that prevents midday dosing), they can file a step therapy exception. Anthem's criteria for granting exceptions include documented clinical need, prior adverse reaction to IR formulation, or safety concerns with IR administration in the patient's specific circumstances.

One practical workaround: some prescribers write for twice-daily IR dosing initially, document the adherence or tolerability issues that arise, and then submit the PA for XR with that clinical evidence. This approach satisfies step therapy requirements while building a real-world clinical record.

What to Do if Anthem Denies Coverage

A denial is not the final answer. Anthem's internal appeals process has three levels, and federal regulations under the Affordable Care Act guarantee your right to an external review after exhausting internal appeals.

The first step is an internal appeal, which must be filed within 180 days of the denial notice. You (or your prescriber on your behalf) submit additional clinical documentation supporting the medical necessity of the specific medication. Anthem must respond within 30 calendar days for standard appeals or 72 hours for expedited appeals involving active treatment.

Second-level internal appeals bring additional clinical reviewers into the decision. If the second-level appeal is denied, you can request an external review by an independent review organization (IRO). A study in Health Affairs found that external reviews of prescription drug denials overturned the insurer's decision in 39% to 54% of cases across major commercial insurers from 2018 to 2022 [9].

Key documents to include in any appeal: the prescriber's letter of medical necessity citing DSM-5 diagnostic criteria, documentation of prior medication trials and outcomes, relevant clinical guidelines (AAP for pediatric cases, APA for adults), pharmacy claims history showing step therapy compliance, and any relevant neuropsychological testing results.

For Medicaid managed-care members, the appeal process includes the additional right to a state fair hearing if internal and external appeals fail. Contact your state's Department of Insurance or Medicaid agency for state-specific timelines and procedures.

Alternatives Anthem Covers Without Prior Authorization

If the prior authorization process creates delays that affect your treatment, several ADHD medications are covered on most Anthem formularies without PA requirements.

Generic methylphenidate IR (Ritalin equivalent) sits on Tier 1 or Tier 2 on nearly all Anthem plans with no PA or step therapy. Generic methylphenidate ER (Concerta equivalent, specifically the authorized generic by Patriot Pharmaceuticals) is Tier 2 on most formularies, though some plans still require PA for extended-release formulations.

Atomoxetine (generic Strattera) is a non-stimulant option on Tier 2 of most Anthem commercial formularies. A Cochrane review of 25 randomized controlled trials (N=3,928) found atomoxetine produced a standardized mean difference of -0.45 for ADHD symptom reduction compared to placebo, which is a moderate effect size [10]. This is smaller than the effect size for amphetamine salts (SMD -0.91) but meaningful for patients who cannot tolerate stimulants or who have comorbid anxiety.

Guanfacine ER (generic Intuniv) and clonidine ER (generic Kapvay) are alpha-2 agonists approved for pediatric ADHD. Both generics are on Tier 2 for most Anthem plans. These are particularly useful as adjuncts to stimulants or as monotherapy when stimulants are contraindicated due to cardiovascular concerns, tic disorders, or substance use history.

Viloxazine ER (Qelbree) is a newer non-stimulant that received FDA approval in 2021 for both pediatric and adult ADHD [11]. On Anthem formularies, it is typically Tier 3 with PA required. The prescribing information reports a statistically significant reduction in ADHD-RS-5 total score versus placebo (mean difference of -4.5 points, P<0.001 in the adult key trial).

Tips for Minimizing Your Adderall Costs on Anthem

Start by confirming your plan's preferred pharmacy network. Anthem contracts with CVS, Walgreens, Walmart, and independent pharmacies, but copays vary by pharmacy tier. Using a non-preferred pharmacy can add $10 to $25 per fill.

Request 90-day mail-order fills through IngenioRx or your plan's designated mail-order pharmacy. Most Anthem plans charge two copays for a 90-day supply instead of three, saving roughly 33% annually.

If you take generic IR tablets, ask your prescriber about the 20 mg strength. Tablets at 20 mg and 30 mg often have the same copay, and pharmacists can split or adjust quantities to minimize fills. The per-tablet cost of amphetamine salt combination 20 mg tablets averaged $0.88 in 2024 according to the National Average Drug Acquisition Cost (NADAC) database maintained by the Centers for Medicare and Medicaid Services [12].

For patients on high-deductible health plans (HDHPs) with health savings accounts (HSAs), prescription costs count toward the deductible and out-of-pocket maximum. Track your cumulative spending carefully because once you hit the out-of-pocket maximum ($9,200 for individual coverage in 2025), your plan covers 100% of remaining prescription costs for the year.

Teva Pharmaceuticals offers a copay savings card for its authorized generic Adderall XR that can reduce out-of-pocket costs to as low as $25 per fill for commercially insured patients. This card does not apply to government-funded plans (Medicare, Medicaid, TRICARE).